ArticleInternational journal of molecular sciences2018
Fewer Functional Deficits and Reduced Cell Death after Ranibizumab Treatment in a Retinal Ischemia Model.
Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 28 citations in OpenAlex.
- Mechanisms of action of retinal microglia in diabetic retinopathy (Review).International journal of molecular medicine · 2025Review
- Retinal degeneration driven by brain-derived neurotrophic factor deficiency in microglia and T-lymphocytes.Scientific reports · 2025Article
- Inhibition of Vascular Endothelial Growth Factor Reduces Photoreceptor Death in Retinal Neovascular Disease via Neurotrophic Modulation in Müller Glia.Molecular neurobiology · 2025Article
- Microglia in retinal angiogenesis and diabetic retinopathy.Angiogenesis · 2024Review
- Dose-Related Side Effects of Intravitreal Injections of Humanized Anti-Vascular Endothelial Growth Factor in Rats: Glial Cell Reactivity and Retinal Ganglion Cell Loss.Investigative ophthalmology & visual science · 2024Article
- In a novel autoimmune and high-pressure glaucoma model a complex immune response is induced.Frontiers in immunology · 2024Article
- Enhanced glaucomatous damage accompanied by glial response in a new multifactorial mouse model.Frontiers in immunology · 2022Article
- Microglia Activation in Retinal Ischemia Triggers Cytokine and Toll-Like Receptor Response.Journal of molecular neuroscience : MN · 2021Article
- Activation of Apoptosis in a βB1-CTGF Transgenic Mouse Model.International journal of molecular sciences · 2021Article
- Synthesis, Characterization, andFrontiers in pharmacology · 2021Article
- Effect of anti-VEGF treatment on nonperfusion areas in ischemic retinopathy.International journal of ophthalmology · 2021Review
- Cytokine and Complement Response in the Glaucomatous βB1-CTGF Mouse Model.Frontiers in cellular neuroscience · 2021Article
- Microvascular Structure Changes After Intravitreal Ranibizumab Injection in Retinal Vein Occlusion Patients With and Without Macular Ischemia.Frontiers in medicine · 2021Article
- Minocycline reduces inflammatory response and cell death in a S100B retina degeneration model.Journal of neuroinflammation · 2020Article
- Clinical effect of conbercept on improving diabetic macular ischemia by OCT angiography.BMC ophthalmology · 2020Article
- Article
- Role of the PGE2 receptor in ischemia-reperfusion injury of the rat retina.Molecular vision · 2020Article
- Loss of retinal ganglion cells in a new genetic mouse model for primary open-angle glaucoma.Journal of cellular and molecular medicine · 2019Article
- Transfer of the Experimental Autoimmune Glaucoma Model from Rats to Mice-New Options to Study Glaucoma Disease.International journal of molecular sciences · 2019Article
- Intravitreal Therapy Against the Complement Factor C5 Prevents Retinal Degeneration in an Experimental Autoimmune Glaucoma Model.Frontiers in pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinal ischemia is an important factor in several eye disorders. To investigate the impact of VEGF inhibitors, as a therapeutic option, we studied these in a retinal ischemia animal model. Therefore, animals received bevacizumab or ranibizumab intravitreally one day after ischemia induction. Via electroretinography, a significant decrease in a- and b-wave amplitudes was detected fourteen days after ischemia, but they were reduced to a lesser extent in the ranibizumab group. Ischemic and bevacizumab retinae displayed fewer retinal ganglion cells (RGCs), while no significant cell loss was noted in the ranibizumab group. Apoptosis was reduced after therapy. More autophagocytotic cells were observed in ischemic and bevacizumab eyes, but not in ranibizumab eyes. Additionally, more microglia, as well as active ones, were revealed in all ischemic groups, but the increase was less prominent under ranibizumab treatment. Fewer cone bipolar cells were detected in ischemic eyes, in contrast to bevacizumab and ranibizumab-treated ones. Our results demonstrate a reduced apoptosis and autophagocytosis rate after ranibizumab treatment. Furthermore, a certain protection was seen regarding functionality, RGC, and bipolar cell availability, as well as microglia activation by ranibizumab treatment after ischemic damage. Thus, ranibizumab could be an option for treatment of retinal ischemic injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.